Search research articles
Contact Us
Filters
Showing results (181-190 of 199) with videos related to
Page
of 20
Sort By:
JCI Insight
|
May 18, 2021
Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma
Ling Li, Gilad Halpert, Michael G Lerner, et al.
Cancer Medicine
|
December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Mark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.
The Lancet. Gastroenterology & Hepatology
|
July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A Lowery, Howard A Burris, Filip Janku, et al.
Hepatology (Baltimore, Md.)
|
July 1, 2025
Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma
Jacklyn N Hammons, Emilie K Warren, Megen C Wittling, et al.
Nature Communications
|
November 12, 2024
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial
Marina Baretti, Ludmila Danilova, Jennifer N Durham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Nature Communications
|
June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial
Hejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Oncoimmunology
|
November 15, 2021
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection
Daniel Delitto, Daniel J Zabransky, Fangluo Chen, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 199) with videos related to
Sort By:
Page
of 20
JCI Insight
|
May 18, 2021
Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma
Ling Li, Gilad Halpert, Michael G Lerner, et al.
Cancer Medicine
|
December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Mark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.
The Lancet. Gastroenterology & Hepatology
|
July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A Lowery, Howard A Burris, Filip Janku, et al.
Hepatology (Baltimore, Md.)
|
July 1, 2025
Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma
Jacklyn N Hammons, Emilie K Warren, Megen C Wittling, et al.
Nature Communications
|
November 12, 2024
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial
Marina Baretti, Ludmila Danilova, Jennifer N Durham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Nature Communications
|
June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial
Hejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Oncoimmunology
|
November 15, 2021
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection
Daniel Delitto, Daniel J Zabransky, Fangluo Chen, et al.
Page
of 20